Ligand Pharmaceuticals (NASDAQ:LGND) Cut to “Sell” at StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. Several other brokerages also recently commented on LGND. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $142.00 to $145.00 and gave the stock an “outperform” […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. Several other brokerages also recently commented on LGND. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $142.00 to $145.00 and gave the stock an “outperform” […]
